Eribulin Elicits Promising 2-Year Overall Survival in Pretreated Metastatic Breast Cancer
Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
